Table 2.

Treatment and patient outcomes

	All patients (n = 68)		Low sPD-L1 (n = 36)		High sPD-L1 (n = 32)
	n	(%)	n	(%)	n	(%)	P
HD-MTX chemotherapy
Completed	61	(90)	32	(89)	29	(91)	>  0.999
Failed to complete	7	(10)	4	(11)	3	(9)
Response to HD-MTX treatment
CR/PR	54/12	(97)	30/6	(100)	24/6	(94)	0.486
SD/PD	1/1	(3)	0/0	(0)	1/1	(6)
Intrathecal chemotherapy
Combined	26	(38)	10	(28)	16	(50)	0.081
Not combined	42	(62)	26	(72)	16	(50)
Whole brain radiotherapy
Done	45	(66)	24	(67)	21	(67)	>  0.999
Not done	23	(34)	12	(33)	11	(34)
Relapse after primary treatment
No relapse	29	(43)	18	(50)	11	(34)	0.226
Relapse	39	(57)	18	(50)	21	(66)
Autologous stem cell transplantation
Done	12	(18)	7	(19)	5	(16)	0.758
Not done	56	(82)	29	(81)	27	(84)
Relapse or progression
None	25	(37)	18	(50)	7	(22)	0.023
Occurred	43	(63)	18	(50)	25	(78)
Survival status
Alive	39	(57)	27	(75)	12	(37)	0.003
Dead	29	(43)	9	(25)	20	(63)